$ACHV

Achieve announced it closed a $261.5M securitization of newly originated HELOCs, its first deal of 2026 and ninth overall. The pool covers 3,129 lines with about $261.5M unpaid principal and $276.5M total credit line as of June 30. S&P Global Ratings and Morningstar DBRS assigned ratings to six rated and three unrated note classes.

Achieve closed a $261.5 million AAA-rated HELOC securitization on July 30, 2026, called ACHM Trust 2026-HE1, backed by 3,129 newly originated HELOCs. The deal has six rated note classes and three unrated classes, with weighted average seasoning of three months and weighted average combined LTV of 65.67%, according to the company.

ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K --12-31 false 0000949858 BC 0000949858 2026-07-02 2026-07-02 0000949858 dei:OtherAddressMember 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act

Achieve Life Sciences (NASDAQ:ACHV) rose 9.3% to $5.38 on Thursday after closing at $4.92; it traded as high as $5.50 on volume of 725,384 shares. Analysts cited mixed views: Canaccord set a $13 target (buy) and HC Wainwright set $12 (buy), while Weiss downgraded to sell (d-). The company reported ($0.19) EPS vs ($0.30) consensus on May 12.

Achieve Life Sciences has appointed three former Verona Pharma executives, Christopher Martin, Mark Zappia, and Jim Willis, to its board and commercial leadership team. This move aims to strengthen Achieve's path toward commercializing cytisinicline for nicotine dependence. The new hires previously led the successful U.S. launch of Ohtuvayre for Verona Pharma, which was later acquired by Merck for $10.8 billion.

Achieve Life Sciences (ACHV) reported a Q1 2026 net loss of $10.2 million but closed a significant private placement of up to $354 million, with $180 million upfront, to fund its lead drug candidate, cytisinicline. The company expects an FDA Complete Response Letter by June 20, 2026, due to issues at a prior manufacturer, but plans to resubmit its New Drug Application (NDA) in Q4 2026 with a new manufacturing partner, Adare Pharma Solutions, targeting a U.S. launch in the first half of 2027. This financing and strategic shift are intended to advance cytisinicline, a potential first new FDA-approved smoking cessation therapy in over two decades, towards commercialization.

Achieve Life Sciences announced its first-quarter 2026 financial results, highlighted by a successful private placement of up to $354 million to fund its ORCA-V2 Phase 3 trial and commercialization of cytisinicline. The company also appointed Andrew D. Goldberg, MD, as CEO, expanded its board, and transitioned to U.S.-based manufacturing with Adare Pharma Solutions, despite an expected Complete Response Letter from the FDA necessitating a resubmission in Q4 2026 for a planned Q1 2027 commercial launch.

Achieve Life Sciences has completed the transfer of cytisinicline manufacturing to Adare Pharma Solutions in Vandalia, Ohio, establishing U.S.-based production and supply-chain redundancy. This move comes after a third-party manufacturing facility received an Official Action Indicated (OAI) classification from the FDA. Achieve expects a Complete Response Letter by June 20, 2026, plans to resubmit its New Drug Application naming Adare in Q4 2026, and anticipates a commercial launch in the first half of 2027.

Achieve Life Sciences Inc (ACHV) is anticipated to report a loss of 27 cents per share. This financial forecast comes as an earnings preview from Refinitiv and Reuters. The information is based on current financial analysis.

Achieve Life Sciences (Nasdaq: ACHV) announced it will report its Q4 and full-year 2025 financial results and provide a corporate update on its cytisinicline development program on March 24, 2026. The company's New Drug Application for cytisinicline as a nicotine dependence treatment for smoking cessation was accepted by the FDA in September 2025, with a PDUFA date of June 20, 2026. Investors can access a webcast and conference call to hear the updates.